Stockreport

Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monocl...

Tiziana Life Sciences Ltd - Common Shares  (TLSA) 
PDF Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-toleratedThe scientific approaches underlying this clinical stud [Read more]